Orexigen (OREX) reports a quarterly loss of $0.24 vs. an expected -$0.21, but is still hopeful...

|About: Orexigen Therapeutics, Inc. (OREX)|By:, SA News Editor

Orexigen (OREX) reports a quarterly loss of $0.24 vs. an expected -$0.21, but is still hopeful about obesity drug Contrave : "we have been preparing for a meeting with FDA to discuss a viable path forward for Contrave... [and] have submitted to the Agency a specific, innovative, and robust proposal to assess cardiovascular risk..." (PR)